Auxilium sues Watson on testosterone gel patent
(Reuters) - Auxilium Pharmaceuticals Inc sued Watson Pharmaceuticals Inc alleging that it infringed patents related to Auxilium's testosterone gel Testim.
A unit of Watson had filed with U.S. health regulators last month for the approval of a generic version of Testim.
As a result of the lawsuit, regulatory approval of Watson's generic version will be stayed for 30 months, or until the litigation is resolved, Auxilium said.
In its suit, Auxilium alleged that Watson's gel infringed ten patents that are expected to expire between 2023 and 2025.
Auxilium had entered into a co-promotion agreement with a unit of GlaxoSmithKline on Monday to jointly sell Testim.
Shares of Auxilium, which have risen 10 percent since the company entered into the GlaxoSmithKline agreement, closed at $19.23 on Wednesday on the Nasdaq. Watson shares were at $70.71 at close on the New York Stock Exchange on Wednesday.
(Reporting by Adithya Venkatesan in Bangalore; Editing by Sreejiraj Eluvangal)
- Tweet this
- Share this
- Digg this
- Russia can run on empty for a year if sanctions block new bonds
- U.S. strikes have slowed Iraq militants but not weakened them - Pentagon
- Actress Jennifer Lawrence contacts authorities after nude photos hacked
- Nasty, brutish and artsy? Neanderthal hashtag engraving found
- Mumbai hit by big power cuts after technical glitch at Tata Power unit
The world's "disastrously inadequate response" to West Africa's Ebola outbreak means many people are dying who could easily be saved, the head of the World Bank said on Monday, as Nigeria confirmed another case of the highly contagious virus. Full Article